Life Sciences & Healthcare Transactions

EMA professionals have served in an advisory capacity on the following transactions:


  • Advised Solulink, LLC, a maker of proprietary life science conjugation technologies, on a sale of certain assets to Maravai Life Sciences. Terms undisclosed.
  • Represented Wasatch Microfluidics, LLC, a manufacturer of instrumentation for antibody screening, in a $10 million Series D preferred equity capital raise from Telegraph Hill Partners. Terms undisclosed.*
  • Represented Avansci Bio, LLC, a manufacturer of tissue dissection instrumentation used in oncology diagnostics, in sale to Roche Diagnostics. Terms undisclosed.
  • Represented Affymetrix, Inc. in its sale of Anatrace, a manufacturer of detergents for membrane protein research, to StoneCalibre Partners. Terms undisclosed.
  • Sale of Transpire, Inc., a maker of radiation treatment planning software, to Varian Medical Systems. Terms undisclosed.
  • Sale of Sandhill Scientific, a manufacturer of gastrointestinal devices, to Medovations, Inc. Terms undisclosed.*
  • Sale of Aribex Inc., a manufacturer of dental imaging systems, to Danaher Corporation to a top five global medical device maker. Terms undisclosed.*
  • Consulted with One Lambda, Inc., a life science technologies company, in its sale to ThermoFisher Scientific, Inc. Terms undisclosed.
  • Sale of Braun BioSystems, Inc. to Medtronic, Inc. Terms undisclosed.
  • Sale of Premier Medical, Inc., a respiratory services company, to The Riverside Company. Terms undisclosed.*
  • Advised Advanced Cell Diagnostics, Inc., a maker of diagnostic tests for personalized medicine, on transaction with Ventana Medical Systems/Roche Diagnostics. Terms undisclosed.
  • Represented BioMicro Systems, Inc. in its sale of all intellectual property assets relating to NimbleGen microarrays to Roche Diagnostics. Terms undisclosed.
  • Sale of MicroBiologics, Inc., a producer of biological standards for laboratory use, to Granite Equity Partners. Transaction valued at $14 million.
  • Sale of Airlift Unlimited, Inc., a producer of respiratory therapy devices, to Meridian Medical, LLC. Terms undisclosed.*
  • Sale of First Opinion Corporation, a healthcare diagnostics software company, to Healthways, Inc. (HWAY). Terms undisclosed.
  • Represented One Lambda, Inc. in licensing agreement with Luminex Corporation. Terms undisclosed.
  • Sale of Panomics, Inc., a manufacturer of reagents and DNA expression technologies for life science research applications, to Affymetrix, Inc. (AFFY). Terms undisclosed.
  • Sale of Environmental Resource Associates, Inc., a manufacturer of environmental standards for laboratory equipment, to Waters Corporation (WAT). Terms undisclosed.
  • Represented Genaissance Pharmaceuticals, Inc. (GNSC), in its acquisition of Lark Technologies, Inc., a gene sequencing service company. Transaction valued at $10 million.
  • $12 million preferred equity financing for GenoSpectra, Inc., a life sciences reagent company.
  • Represented a $50 million revenue life sciences instrumentation and reagent company through multiple transactions, 9 in-licensing and acquisition projects, and the divestiture of one business unit. Terms undisclosed.
  • Acquisition of the life science instrumentation division of GSI Lumonics, Inc. Transaction valued at $120 million.
  • Initial public offering of Packard BioScience Company, a manufacturer of automated laboratory equipment and reagents for life science research applications. Transaction valued at $150 million.
  • Merger of Packard BioScience Company with PerkinElmer, Inc. (PKI). Transaction valued at over $700 million.
  • Sale of Canberra Industries, Inc., a manufacturer of nuclear detection instrumentation, to COGEMA, Inc. Transaction valued at $180 million.
  • Represented buyer in acquisition of a $4 million revenue life sciences tool company with a unique labeling technology for life science research applications. Terms undisclosed.
  • Sale of Immunex Corporation, a leader in immune system science innovation and manufacturer of leading rheumatoid arthritis drug, ENBREL, to Amgen Corporation (AMGN). Transaction valued at $16 billion.
  • Acquisition of Tularik, a pioneer in drug discovery related to cell signaling and the control of gene expression, by Amgen Corporation (AMGN). Transaction valued at $1.3 billion.
  • Negotiation of joint venture technology development agreements with multi- billion dollar medical device manufacturer. Terms undisclosed.
  • Acquisition of multiple, independent nuclear detection instrumentation businesses in the U.S. and Europe. Transaction valued at over $20 million.
  • Acquisition of Canadian life science tools distribution company. Transaction valued at $10 million.
  • Acquisition of fiber-optic imaging business in the U.K. Terms undisclosed.
  • Negotiation of license, joint development and distribution agreements with Sigma-Aldrich Corporation (SIAL) on behalf of early-stage biomarker and reagent company. Terms undisclosed.
  • Negotiation of joint venture and licensing agreement with microfluidics company. Terms undisclosed.
  • Negotiation of license agreement with Luminex, Inc. (LMNX). Terms undisclosed.
  • Negotiation of license agreement for biomarker technology with Scripps Institute. Terms undisclosed.
  • Negotiation of license and distribution agreement for gene expression technology with Bayer Healthcare, LLC, Diagnostics Division. Terms undisclosed.
  • Negotiation of license agreement for fluorescent marker technology with Albert Einstein College of Medicine. Terms undisclosed.
  • Negotiation of technology license agreements with The University of North Carolina at Chapel Hill, and the Centre National De Recherche Scientifique (CNRS). Terms undisclosed.
  • Sale of Elekon Industries, Inc., a medical sensor company, to Measurement Specialties, Inc. (MSS). Terms undisclosed.
  • Sale of Aerosport Corporation, a manufacturer of metabolic analysis equipment for clinical and sports applications, to Angeion Corporation (ANGN). Terms undisclosed.
  • Sale of TERM Billing, Inc., a medical billing company, to Intermedix, Inc. with equity backing from Parthenon Capital. Terms undisclosed.
  • Recapitalization of Emergency Care & Health Organization, Ltd., a physician practice company. Terms undisclosed.

*Principals of EMA acted in their capacity of registered securities agents of Burch & Company, Inc., Member Finra/SiPC on these transactions.

Back to Sectors